Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11558185 | 1.00 | CCNT1 (0.49) | CCNT1CCNA2CDK2CDK9SLC6A2 | |
| SCHEMBL11558180 | 1.00 | CCNT1 (0.49) | CCNT1CCNA2CDK2CDK9SLC6A2 | |
| SCHEMBL6707683 | 1.00 | CCNT1 (0.49) | CCNT1CCNA2CDK2CDK9SLC6A2 | |
| SCHEMBL14186235 | 0.85 | SLC6A3 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6042661 | 0.83 | SLC6A3 (0.60) | SLC6A3 | |
| SCHEMBL463706 | 0.83 | SLC18A3 (0.58) | CCNT1CCNA2CDK2CDK9SLC6A2 | |
| SCHEMBL11562671 | 0.83 | SLC18A3 (0.58) | CCNT1CCNA2CDK2CDK9SLC6A2 | |
| SCHEMBL11558947 | 0.83 | SLC18A3 (0.58) | CCNT1CCNA2CDK2CDK9SLC6A2 | |
| SCHEMBL11558939 | 0.83 | SLC18A3 (0.58) | CCNT1CCNA2CDK2CDK9SLC6A2 | |
| SCHEMBL11562664 | 0.83 | SLC18A3 (0.58) | CCNT1CCNA2CDK2CDK9SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167163-A1 | Optically pure paroxetine precursors | ASTUR-PHARMA, S.A. (ES) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167163-A1 | Optically pure paroxetine precursors | CYP3A5, TPH2, MAOA | CCNT1 2307/4885CCNA2 1513/4885CDK2 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.